Professional Marketing briefs: Biogen Idec, inVentiv Health, Abbott and Gilead Sciences

Share this article:

Biogen Idec's Tony Kingsley was promoted to run global commercial operations. Kingsley, was previously SVP US commercial operations, with responsibility for marketing, sales, market access, patient services, training and sales ops.

InVentiv Health said its Selling Solutions business will give outsourced sales operations support to pharma company Santarus, as well as recruiting and sales force automation services for the Santarus' prescription diabetes products.

Abbott put aside $1.5 billion for settlement of charges that it marketed epilepsy drug Depakote off label, the Chicago Tribune reported. An ex-rep whistleblower in the case alleges that sales trainees were first told not to market drugs off label, then told by an experienced rep to ignore that order and push the drug for an unapproved use—treatment of agitation associated with dementia.

Gilead Sciences licensed Tibotec's single-tablet combo of Prezista and Gilead's Emtriva for HIV. Under the deal, Gilead will lead formulation, manufacturing, registration and, if approved, distribution and commercialization globally, while Tibotec will have the right to co-detail the combo in certain major markets.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro